Skip to Content

Brainstorm Cell Therapeutics Inc BCLI

Morningstar Rating
$0.35 −0.02 (5.94%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BCLI is trading at a 44% discount.
Price
$0.35
Fair Value
$4.25
Uncertainty
Extreme
1-Star Price
$2.24
5-Star Price
$1.95
Economic Moat
Hsgj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCLI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.37
Day Range
$0.340.37
52-Week Range
$0.133.46
Bid/Ask
$0.35 / $0.36
Market Cap
$16.91 Mil
Volume/Avg
194,738 / 2.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
42

Comparables

Valuation

Metric
BCLI
KROS
PLRX
Price/Earnings (Normalized)
Price/Book Value
6.602.09
Price/Sales
614.69
Price/Cash Flow
Price/Earnings
BCLI
KROS
PLRX

Financial Strength

Metric
BCLI
KROS
PLRX
Quick Ratio
0.2313.6317.43
Current Ratio
0.2414.2517.72
Interest Coverage
−1,385.00−145.34
Quick Ratio
BCLI
KROS
PLRX

Profitability

Metric
BCLI
KROS
PLRX
Return on Assets (Normalized)
−179.42%−35.62%−22.68%
Return on Equity (Normalized)
−39.15%−24.50%
Return on Invested Capital (Normalized)
−1,360.88%−41.95%−28.46%
Return on Assets
BCLI
KROS
PLRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJbp$550.4 Bil
VRTX
Vertex Pharmaceuticals IncFchsxj$111.8 Bil
REGN
Regeneron Pharmaceuticals IncBsbblfd$107.9 Bil
MRNA
Moderna IncJwvd$36.3 Bil
ARGX
argenx SE ADRRhbbq$23.0 Bil
BNTX
BioNTech SE ADRWtnmk$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncWczwvhq$19.2 Bil
BMRN
Biomarin Pharmaceutical IncCjnnt$16.4 Bil
RPRX
Royalty Pharma PLC Class AJfgsjdd$13.4 Bil
INCY
Incyte CorpNgdbq$13.3 Bil

Sponsor Center